UroGen Pharma
URGN
84 hedge funds and large institutions have $347M invested in UroGen Pharma in 2019 Q3 according to their latest regulatory filings, with 16 funds opening new positions, 41 increasing their positions, 13 reducing their positions, and 14 closing their positions.
215% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 13
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
0% more funds holding
Funds holding: 84 → 84 (0)
0.92% less ownership
Funds ownership: 70.62% → 69.69% (-0.92%)
28% less call options, than puts
Call options by funds: $1.63M | Put options by funds: $2.26M
34% less capital invested
Capital invested by funds: $527M → $347M (-$180M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$24.4M |
| 2 |
MIFH
Migdal Insurance & Financial Holdings
Petach Tikva,
Israel
|
+$13.7M |
| 3 |
WCM
Wildcat Capital Management
New York
|
+$6.95M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$5.5M |
| 5 |
Goldman Sachs
New York
|
+$2.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
-$51.5M |
| 2 |
MIH
Meitav Investment House
Bene-Beraq,
Israel
|
-$10.4M |
| 3 |
HCM
Highline Capital Management
New York
|
-$4.48M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.27M |
| 5 |
Millennium Management
New York
|
-$2.6M |
URGN Hedge Fund Activity: Q3 2019 in Review
84 of the 4,574 institutional investors tracked by Wall St. Rank reported a position in UroGen Pharma (URGN) for Q3 2019, worth a combined $347M — down 34% from $527M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new URGN positions and 14 closed out — a net gain of 2 holders — while 41 added to existing stakes and 13 trimmed.
The largest buyer was Baker Bros. Advisors, opening a new position worth an estimated $24.4M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $51.5M sold.
- 84 institutional investors held UroGen Pharma (URGN) as of Q3 2019, unchanged from Q2 2019.
- Funds reported $347M of UroGen Pharma stock for Q3 2019, down 34% quarter-over-quarter.
- 16 funds opened new UroGen Pharma positions in Q3 2019 and 14 closed out, a net change of +2 holders.
- The largest UroGen Pharma buyer in Q3 2019 was Baker Bros. Advisors, an estimated $24.4M added.
- The largest UroGen Pharma seller in Q3 2019 was Consonance Capital Management, an estimated $51.5M sold.
Based on aggregated 13F filings for Q3 2019.